Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

By taking 36 mg once per day - without food and water restrictions - participants lost an average of 12.4 percent of their body weight - about 27.3 pounds (12.4 kilograms). This was over the span of ...

Several studies have found patients taking GLP-1 medications like Wegovy and Mounjaro regain weight, sparking fresh health advice from experts.

Lilly's stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook. A previous report had an incorrect company name.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Vizient released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...